Balances - Correction of the Requirements in the U.S. Pharmacopoeia (USP)
Recommendation

17/18 November 2026
Heidelberg, Germany
Enhanced Approach using AQbD Principles
In the Pharmacopoeial Forum 40(1) a short-term revision of the General Chapter <41> with regard to balances was announced as "interim revision announcement".
Questions that arrived at the USP indicate that there is a potential problem with the requirement of repeatability in the verification of scales. If you follow the procedure as described, the use of a large test weight can cause false positive results.
To resolve this problem, the expert group of the USP proposes a modified test in which the "smallest desired net weight" is now incorporated in the formula for the repeatability as well.
If there are no contrary comments, this "interim revision announcement" will become effective as of 1 July 2014.
All other information are available on the USP website of the Pharmacopeial Forum (PF).
Source: USP - http://www.USP.org
Related GMP News
02.11.2026FDA Warning Letter: When Test Procedures Allow Retesting Until an Acceptable Result is Obtained
21.10.2026EMA Updates Information Page on Bioequivalence Guidelines
21.10.2026BP Publishes new Draft Texts
21.10.2026FDA Identifies Critical Deficiencies in Analytical Testing and CGMP Oversight
07.10.2026Analytical Quality Group Developments May through August 2026
07.10.2026Two New FDA Warning Letters Put OOS Investigations in Focus


